The BioPharm Brief: Advancing ADCs, Biosimilars and CAR-T Therapies

Oct 07, 07:53 PM
Headliner
Share
Subscribe

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and drug development. Today’s update looks at new FDA breakthrough designations for a targeted cancer therapy, expanded biosimilar manufacturing capacity, the US launch of an interchangeable biosimilar, and a setback for allogeneic chimeric antigen receptor T cell (CAR-T) therapy development.

Share
Subscribe
Next
The BioPharm Brief: Advancing Parkinson, Kidney, Obesity and Cancer Care
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief